Overview

AltA-ZuZ has developed a novel, first in class, orally bioavailable, small molecule for the treatment of autoimmune diseases. We have shown our molecule is a potent blocker of both B and T cell trafficking, far superior to other currently available therapies (Tysabri). Our molecule was shown to be safe in multiple administration routes (oral, IV, subcutaneous) and has shown impressive efficacy in mouse models of Inflamed Bowel Disease, Multiple Sclerosis, fatty liver disease, and collagen-induced arthritis